Jade Biosciences, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 7.09M | $99.55M | 0.01% | Added+2.8% | 2026-03-31 |
| StateStreet | passive | 655.7K | $9.21M | 0.00% | Added+2.0% | 2026-03-31 |
| Citadel | multi-strat | 264.3K | $3.71M | 0.00% | Trimmed-52.7% | 2026-03-31 |
| RenTech | quant | 135.0K | $1.90M | 0.00% | Added+94.0% | 2026-03-31 |
| Wellington | fundamental | 129.2K | $1.81M | 0.00% | Added+25.9% | 2026-03-31 |
| TwoSigma | quant | 18.3K | $256.43K | 0.00% | Added+10.6% | 2026-03-31 |
| TRowePrice | fundamental | 22.6K | $318 | 0.00% | Trimmed-10.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.62 | — | — |
| 2026-05-07 | -0.48 | -0.57 | -19.37% |
| 2025-11-12 | -0.67 | -0.48 | +28.36% |
| 2025-08-13 | -0.48 | -0.86 | -79.17% |
| 2025-05-14 | -2.05 | -12.10 | -490.24% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| JBIO | -13.17% | +51.26% | +36.36% | +190.21% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -16.13% | +55.90% | +39.80% | +177.52% |